Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: Pharmacological re-activation of viral target genes with arginine butyrate

Transplant Infectious Disease

Volumn 3, Issue 3, 2001, Pages 177-185

  Mentzer, S J ^a,b   Perrine, S P ^a,b   Faller, D V ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arginine butyrate; Epstein Barr virus; Post transplant lymphoproliferative disease; Viral target genes; Virus specific therapy

Indexed keywords

ANTIVIRUS AGENT; ARGININE BUTYRATE; BUTYRIC ACID DERIVATIVE; GANCICLOVIR; IMMUNOLOGIC AGENT; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE INDUCTION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LETHARGY; LUNG TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ARGININE; BUTYRATES; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; LUNG NEOPLASMS; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; TUMOR CELLS, CULTURED; VIRUS LATENCY;

EID: 0034870826     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2001.003003177.x     Document Type: Article

References (91)

1. A sarcoma involving the jaws in African children
2. Virus particles in cultured lymphoblasts from Burkitt's lymphoma
3. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy
4. Pseudolymphoma in renal allograft recipients
5. Epstein-Barr virus-associated diseases in humans
6. The role of EBV in post-transplant malignancies: A review
7. Chronic, active Epstein-Barr virus infection
8. Epstein-Barr virus and the immune system. Hide and seek
9. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo
10. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
11. Epstein-Barr virus and its replication
12. Replication of latent Epstein-Barr virus genomes in Raji cells
13. Early events in Epstein-Barr virus infection of human B lymphocytes
14. Replication of the resident repressed Epstein-Barr virus genome during the early S phase (S-1 period) of nonproducer Raji cells
15. The pathogenesis of Burkitt's lymphoma
16. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis
17. X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology
18. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene
19. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome
20. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
21. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
22. Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation
23. Lymphoma of host origin in a marrow transplant recipient in remission of acute myeloid leukemia and receiving cyclosporin A
24. Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation
25. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: Polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4
26. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma
27. Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart-lung transplantation
28. Malignant lymphoma in the recipient of a heart transplant from a donor with malignant lymphoma. Lymphoma transplantation or de novo disease?
29. A poorly differentiated lymphoma of donor origin in a renal allograft recipient
30. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children
31. Simultaneous development of diffuse immunoblastic lymphoma in recipients of renal transplants from a single cadaver donor: Transmission of Epstein-Barr virus and triggering by OKT3
32. Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein-Barr virus and immunoglobulin genes as markers
33. Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient
34. Rapid development of lymphoma following liver transplantation in a recipient with hepatitis B and primary hemochromatosis
35. Malignant lymphomas in organ transplant recipients
36. Discrimination of Epstein-Barr virus-related post-transplant lymphoproliferations from acute rejection in lung allograft recipients
37. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation
38. Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation
39. Post-transplant mediastinal Burkitt-like lymphoma. Diagnosis by cytologic and flow cytometric analysis of pleural fluid
40. Post-transplant T-cell lymphoma. Report of three cases and a review of the literature
41. Immunoblastic lymphoma of donor origin in the allograft after lung transplantation
42. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
43. Overview of posttransplant B-cell lymphoproliferative disorders
44. The molecular genetics of post-transplantation lymphoproliferative disorders
45. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center
46. Post-transplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression
47. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting
48. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr virus-associated lymphoma
49. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
50. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia
51. Identification of an Epstein-Barr virus-coded thymidine kinase
52. Epstein-Barr virus induces a unique pyrimidine deoxynucleoside kinase activity in superinfected and virus-producer B cell lines
53. Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems
54. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
55. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus
56. Regression of oral hairy leukoplakia after orally administered acyclovir therapy
57. Resolution of oral hairy leukoplakia during therapy with 9-(1,3- dihydroxy-2-propoxymethyl)guanine (DHPG)
58. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors
59. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo
60. Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation
61. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child
62. Clinical pharmacology of sodium butyrate in patients with acute leukemia
63. Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo
64. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders
65. Butyrate in the treatment of sickle cell disease and beta-thalassemia
66. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
67. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals
68. Sodium butyrate induces G2 arrest in the human breast cancer cells MDA- MB-231 and renders them competent for DNA rereplication
69. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity
70. Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line
71. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells
72. Butyrate-induced apoptotic cascade in colonic carcinoma cells: Modulation of the beta-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin
73. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells
74. Butryic acid analogues augment gamma globin gene expression in neonatal erythroid progenitors
75. Epstein-Barr virus infections in the X-linked recessive lymphoproliferative syndrome
76. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation
77. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection
78. A possible association between hepatitis-B antigen-negative infantile popular acrodermatitis and Epstein-Barr virus infection
79. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion
80. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
81. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients
82. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx
83. Epstein-Barr viral DNA in tissues of Hodgkin's disease
84. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B- cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy
85. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections
86. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction
87. Epstein-Barr virus-associated gastric adenocarcinoma
88. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS
89. Epstein-Barr virus in epithelial cell tumors: A breast cancer study
90. Treatment of Epstein-Barr virus (EBV)-associated lymphomas and PTLD using arginine butyrate to induce viral TK gene expression: Initial findings of a phase I/II trial
91. Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus (EBV)-associated lymphomas